THE Therapeutic Goods Administration has approved CSL Behring's new Zemaira, a highly purified Alpha-1 Proteinase Inhibitor to treat select patients with Alpha-1 Antitrypsin Deficiency (AATD), a hereditary lung condition.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Feb 17